Market Exclusive

Eagle Pharmaceuticals,Inc. (NYSE:TEVA) Files An 8-K Shareholder Director Nominations

Eagle Pharmaceuticals,Inc. (NYSE:TEVA) Files An 8-K Shareholder Director NominationsItem 5.08 — Shareholder Director Nominations.

On April 11, 2017, the board of directors, or the Board, of Eagle Pharmaceuticals, Inc., or the Company, approved June 20, 2017 as the date of the Company’s 2017 annual meeting of stockholders, or the Annual Meeting. The record date for the Annual Meeting will be April 25, 2017.

Qualified stockholder proposals (including proposals made to Rule 14a-8 or Rule 14a-18 under the Securities Exchange Act of 1934, as amended, or the Exchange Act, or in the manner contemplated by the Company’s Amended and Restated Bylaws, or the Bylaws) to be presented at the Annual Meeting and included in the Company’s proxy statement and form of proxy relating to that meeting must be received at the Company’s headquarters and addressed to the Company’s corporate secretary. Because the date of the Annual Meeting has been changed to a date that is more than 30 days earlier than the one-year anniversary date of the Company’s 2016 annual meeting of stockholders, in accordance with Rule 14a-18 and the Bylaws, to be timely, such proposal must be received no later than April 24, 2017. For inclusion in the Company’s proxy statement, proposals must comply with applicable Delaware law, the rules and regulations promulgated by the U.S. Securities and Exchange Commission, and the procedures set forth in the Bylaws.

 

About Eagle Pharmaceuticals, Inc. (NYSE:TEVA)
Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams. Its specialty medicines business focuses on delivering a range of solutions to patients and providers through medicines, devices and services in various regions and markets around the world. Its specialty medicines business includes its core therapeutic areas of central nervous system (CNS) and respiratory medicines with a focus on asthma and chronic obstructive pulmonary disease. It also has specialty products in oncology, women’s health and selected other areas. Eagle Pharmaceuticals, Inc. (NYSE:TEVA) Recent Trading Information
Eagle Pharmaceuticals, Inc. (NYSE:TEVA) closed its last trading session down -0.37 at 32.14 with 4,088,079 shares trading hands.

Exit mobile version